Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

Oncolytics Biotech^® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency ("EMA") has granted Orphan Drug Designation for its lead product candidate, REOLYSIN^®, for the treatment of pancreatic cancer.

"Our submission to the EMA included survival data from our single arm gemcitabine/REOLYSIN^® (REO 017) clinical study in pancreatic cancer patients, which factored into their decision to grant us the designation," said Dr. Brad Thompson, President and CEO of Oncolytics.